Group 1 - The company announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the CEP certificate for Oseltamivir Phosphate from the European Medicines Agency [1] - The certificate is effective from July 25, 2025, and is numbered CEP2023-418 [1] - Oseltamivir Phosphate is a selective neuraminidase inhibitor used for the treatment of influenza A and B in adults and children aged one year and older, as well as for prevention in adults and adolescents aged 13 years and older [1] Group 2 - The global sales of the formulation for Oseltamivir Phosphate are projected to reach $1.017 billion in 2024, with a raw material consumption of 92.31 tons [1]

证券代码：300233 证券简称：金城医药 公告编号：2025-052 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司之全资子公司北京金城泰尔制药有限公司 （以下简称"金城泰尔"）于近日收到欧洲药品质量管理局（EDQM）核准签发的 磷酸奥司他韦化学原料药欧洲药典适用性证书(以下简称"CEP 证书"），现将相 关情况公告如下： 一、药品基本情况 化学原料药名称：磷酸奥司他韦 生产企业：北京金城泰尔制药有限公司 证书生效日期：2025 年 7 月 25 日 证书编号：CEP 2023-418 – Rev 00 二、药品相关信息 磷酸奥司他韦是一种选择性的流感病毒神经氨酸酶抑制剂，可以抑制病毒在 体内进一步扩散，由罗氏公司研制开发。目前国内磷酸奥司他韦的相关剂型为胶 囊、颗粒剂和干混悬剂，临床上主要适用于成人、1 岁及 1 岁以上儿童的甲型和乙 型流感治疗，成人、13 岁及 13 岁以上青少年的甲型和乙型流感的预防。根据 IMS 数据查询，2023 年全球制剂销售额 8.74 亿美元，原料药消耗 69.99 吨。2024 年 全球制剂销 ...

Group 1 - The genetically modified concept sector rose by 3.15%, ranking 7th among concept sectors, with 18 stocks increasing, including Shennong Seed Industry which hit the daily limit of 20% [1] - The main inflow of funds into the genetically modified concept sector was 459 million yuan, with 13 stocks receiving net inflows, and 8 stocks seeing inflows exceeding 10 million yuan [2] - Shennong Seed Industry led the net inflow of funds with 292 million yuan, followed by Qianyuan High-Tech, Jincheng Pharmaceutical, and Top Cloud Agriculture [2][3] Group 2 - The top stocks by net inflow ratio included Shennong Seed Industry at 11.98%, Qianyuan High-Tech at 10.45%, and Nongfa Seed Industry at 10.05% [3] - The trading volume and turnover rates for leading stocks were significant, with Shennong Seed Industry showing a turnover rate of 53.68% [3][4] - Other notable stocks included Jincheng Pharmaceutical and Top Cloud Agriculture, with net inflows of 26.61 million yuan and 24.76 million yuan respectively [3]

Group 1 - Senyuan Electric signed a strategic cooperation agreement with Xuchang Digital Supply Chain Management Co., aiming for annual business cooperation not exceeding 500 million yuan over 36 months [1] - CICC's subsidiary, CICC Wealth, reported a net profit of 987 million yuan for the first half of the year, with total assets of 193.37 billion yuan [2] - Shuangjie Electric expects a net profit of 100 million to 120 million yuan for the first half of the year, representing a year-on-year increase of 16.03% to 39.23% [3][4] - Shentong Technology reported a net profit of 64.28 million yuan for the first half of the year, a year-on-year increase of 111.09% [5] - Suqian Nongfa's net profit for the first half of the year decreased by 27.72% to 213 million yuan [6] Group 2 - Fuan Pharmaceutical expects a net profit decline of 39.95% to 53.81% for the first half of the year, estimating between 100 million to 130 million yuan [8] - Xingwang Yuda anticipates a net loss of 11 million to 21 million yuan for the first half of the year [9] - Pulaike received a new veterinary drug registration certificate for a vaccine aimed at preventing chicken diseases [10] - Yuandong Biological's ephedrine injection received a drug registration certificate for treating low blood pressure during anesthesia [11] - Suqian Liansheng's subsidiary obtained two invention patent certificates [12] Group 3 - Oke Technology signed a 176 million yuan equipment order with Jiangxi Tianhong New Materials [13] - Publishing Media announced the resignation of its chief accountant due to work changes [15] - Zhongxin Co. plans to use 40 million yuan of idle funds for cash management [16] - Huiyun Titanium plans to use up to 58 million yuan of idle convertible bond funds for cash management [18] - Haineng Technology intends to apply for a credit facility of up to 200 million yuan from a bank [20] Group 4 - Jiabiou expects a net profit increase of 57.61% for the first half of the year, estimating around 107 million yuan [21] - Nanjing Gaoke reported a 1185% year-on-year increase in contract sales area for the second quarter [22] - Shuguang Co. received approval for a specific stock issuance application [23] - Huadong Pharmaceutical's subsidiary received approval for a clinical trial of a new drug targeting advanced solid tumors [23] - Quicheng Co. plans to invest 900 million yuan in two new projects [25] Group 5 - Shenlian Biological's vaccine for avian adenovirus received a new veterinary drug registration certificate [26] - Rike Chemical signed a strategic cooperation framework agreement with Dongming Petrochemical [28] - Jincheng Pharmaceutical's subsidiary received a renewed tobacco production license [29] - Magmi Te's stock issuance application was accepted by the Shenzhen Stock Exchange [29] - Zhongyin Securities received approval to issue bonds totaling up to 14 billion yuan [29] Group 6 - Hewei Electric's executives plan to reduce their holdings by a total of 2.24% of the company's shares [44] - Guo Wang Xintong reported a net profit of 266 million yuan for the first half of the year, a decrease of 10.82% [45] - Guo Wang Xintong's subsidiary won a 966 million yuan tender from the State Grid [46] - Jicheng Electronics won contracts worth approximately 83.79 million yuan from the State Grid [48] - Helen Piano is planning a change of control, leading to a temporary stock suspension [48]

证券代码：300233 证券简称：金城医药 公告编号：2025-051 山东金城医药集团股份有限公司 关于全资子公司烟草专卖生产企业许可证续期及变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）之全资子公司山东金 城医药化工有限公司（以下简称"金城医化"）于 2025 年 7 月 18 日收到国家烟 草专卖局下发的《烟草专卖生产企业许可证》（电子烟用烟碱生产企业）。本次 下发的《烟草专卖生产企业许可证》将有效期延长至 2028 年 06 月 30 日，并对原 许可证的相关内容进行了变更，现将具体情况公告如下： 一、许可证的主要内容 1、企业名称：山东金城医药化工有限公司 2、许可证编号：3137030055 3、企业住所（主要经营场所、经营场所）：山东省淄博市淄川区昆仑镇晟地 路 288 号 4、法定代表人：韩振友 5、企业类型：有限责任公司（非自然人投资或控股的法人独资） 6、许可范围：电子烟用烟碱生产（内销）；电子烟用烟碱生产（出口） 7、主要出资人：山东金城医药集团股份有限公司（出资比例 100. ...

一、本次质押展期情况 二、股东股份累计质押情况 | | | | | | | 占公 | | 已质押股份情况 未质押股份情况 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次变动前 | 本次展期后 | 占其所 | 司总 | 已质押 | | | 占未 | | 股东 | 持股数量 | 持股比 | | | 持股份 | | 股份限 | | 未质押股 | | | | | | 质押股份数 | 质押股份数 | | 股本 | | 占已质押 | | 质押 | | 名称 | （股） | 例（%） | | | 比例 | | 售和冻 | | 份限售和 | | | | | | 量（股） | 量（股） | （%） | 比例 | 结、标记 | 股份比例 | 冻结数量 | 股份 | | | | | | | | （%） | | （%） | | 比例 | | | | | | | | | 数量 | | （股） | （%） | | | | | | | | | （股） | | | | 关于控股股东部分股份质押展期的公告 本公司及董事会全 ...

证券代码：300233 证券简称：金城医药 公告编号：2025-049 山东金城医药集团股份有限公司 关于子公司收到药品 GMP 符合性检查告知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司全资子公司北京金城泰尔制药有限公司（以 下简称"金城泰尔"）收到北京市药品监督管理局核准签发的《药品 GMP 符合性 检查告知书》（京药监药 GMP〔2025〕020026），现就相关情况公告如下： 一、《药品 GMP 符合性检查告知书》相关信息 企业名称：北京金城泰尔制药有限公司 检查地址：河北省沧州市临港经济技术开发区西区北京医药产业园经五路以 东纬二路以北 检查范围及相关生产车间、生产线：河北省沧州市临港经济技术开发区西区 北京医药产业园经五路以东纬二路以北，原料药富马酸比索洛尔(包装规 格:10kg/桶，批准文号:国药准字 H20057558，登记号:Y20190005788，二车间， 富马酸比索洛尔生产线。 检查类型：依企业申请开展的药品 GMP 符合性检查 二、对公司的影响及风险提示 金城泰尔本次顺利通过药品 GMP 符合 ...

Group 1 - The 42nd National Pharmaceutical Industry Information Annual Conference was held in Beijing from July 5 to 7, organized by the China Pharmaceutical Industry Information Center, which released the list of the top 100 companies by main business revenue for 2024 [1] - China National Pharmaceutical Group continues to rank first, followed by China Resources Pharmaceutical and Qilu Pharmaceutical in second and third places respectively [1] - The conference theme was "Exploring Life, Co-creating the Future," focusing on cutting-edge technology, industrial ecology, and capital empowerment to outline a development blueprint for the Chinese pharmaceutical health industry [1] Group 2 - The pharmaceutical industry in Zibo has over 70 years of development history, forming a comprehensive industrial system that includes drug formulations, active pharmaceutical ingredients, medical devices, and traditional Chinese medicine [2] - In 2024, Zibo's pharmaceutical industry is projected to achieve a revenue of 65 billion yuan with double-digit growth, demonstrating strong industry resilience and development potential [2] Group 3 - Shandong Xinhua Pharmaceutical Co., Ltd. ranked 37th, Ruiyang Pharmaceutical Co., Ltd. ranked 77th, Shandong Qidu Pharmaceutical Co., Ltd. ranked 83rd, and Shandong Jincheng Pharmaceutical Group Co., Ltd. ranked 96th in the top 100 list [1] - Compared to the previous year's rankings, Xinhua Pharmaceutical improved by 3 positions, Ruiyang Pharmaceutical dropped by 14 positions, Qidu Pharmaceutical improved by 4 positions, and Jincheng Pharmaceutical dropped by 5 positions [1]

Group 1 - The core point of the article is that Jincheng Pharmaceutical (300233) announced that its subsidiary, Jincheng Jinsu, received approval from the National Medical Products Administration for the supplementary application of injectable Cefodizime Sodium (0.5g, 1.0g), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] - Injectable Cefodizime Sodium is a third-generation cephalosporin primarily used for infections caused by sensitive bacteria such as Streptococcus and Pneumococcus [1] - According to the data from the China Pharmaceutical Market, the sales revenue of injectable Cefodizime Sodium in public medical institutions in China is projected to be 1.074 billion RMB in 2022, 675 million RMB in 2023, and 394 million RMB in 2024 [1]

证券代码：300233 证券简称：金城医药 公告编号：2025-048 二、药品相关信息 头孢地嗪钠是第三代头孢菌素，临床上主要用于链球菌属、肺炎球菌等敏感 菌所致的肺炎、支气管炎、咽喉炎、扁桃体炎、肾盂肾炎、尿路感染、淋菌性尿 道炎、胆囊炎、胆管炎、妇科感染、败血症及中耳炎等。 中国为头孢地嗪钠主流销售国家。米内网显示 2022 年至 2024 年国内公立医 疗全规格注射用头孢地嗪钠销售额分别为：10.74 亿元人民币、6.75 亿元人民币、 3.94 亿元人民币。截至本公告披露日，国内注射用头孢地嗪钠已批准上市的厂家 包括山东罗欣药业集团股份有限公司、丽珠集团丽珠制药厂、华北制药河北华民 药业有限责任公司、苏州东瑞制药有限公司等企业。 三、对公司的影响及风险提示 本次金城金素获得注射用头孢地嗪钠药品补充申请批准通知书，能够丰富公 司产品线，有利于提升产品的市场竞争力。由于药品销售受国家政策、市场环境 等不确定因素的影响，敬请广大投资者注意风险，理性投资。 山东金城医药集团股份有限公司 关于子公司收到药品补充申请批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导 ...